|
|
|
| Clinical Efficacy of Nerve Growth Factor Combination with Nimodipine in treatment Neonatal Intracranial Hemorrhage and Influence on Plasma PAF CNP MMP-2 and Nerve Function |
| WU Tingting, HE Qiaofeng |
| Yulin First Hospital, Shaanxi Yulin 719000, China |
|
|
|
|
Abstract Objective: To investigate Clinical efficacy of nerve growth factor (NGF) combination with nimodipine in treatment neonatal intracranial hemorrhage (ICH) and influence on plasma platelet activating factor (PAF), c-type natriuretic peptide (CNP), matrix metalloproteinase-2 (MMP-2) and nerve function. Methods: 100 children with ICH in Chuxiong Hospital were randomly divided into observation group and control group. The control group was given basic treatment, while the observation group was given mouse nerve growth factor combined with nimodipine on the basis of the above conventional treatment. The clinical efficacy, plasma levels of PAF, CNP, MMP-2, NABA score and bed performance recovery time before and after treatment were compared between the two groups. Results: After treatment, the total effective rate in observation group was significantly better than the control group ( 92.00% vs 72.00%) (P<0.05). Before treatment, levels of plasma PAF, CNP and MMP-2 and NABA score in the both groups were no significant difference (P>0.05). After treatment 7d and 14d, levels of plasma PAF, CNP and mmp-2 in both groups were decreased and NABA scores was increased, with more significant changes in the observation group and statistically significant differences (P<0.05). The clinical performance in the observation group was significantly shorter than the control group (P<0.05). Conclusion: NGF combined with nimodipine in the treatment of ICH can significantly reduce the levels of plasma PAF, CNP and MMP-2, repair nerve injury, shorten the time of nerve repair and improve the prognosis of ICH, and provide relevant reference for the clinical treatment of ICH.
|
|
|
|
|
|
[1] Oushy S, Parker JJ, Campbell K, et al. Frontal and occipital horn ratio is associated with multifocal intraparenchymal hemorrhages inneonatal shunted hydrocephalus[J].Neurosurg Pediatr,2017,20(5):432~438.
[2] Del Bigio MR, Phillips SM. Retroocular and subdural hemorrhage or hemosiderin deposits in pediatric autopsies[J].Neuropathol Exp Neurol, 2017,76(4):313~322.
[3] McAllister JP, Guerra MM, Ruiz LC, et al. Ventricular zone disruption in human neonates with intraventricular hemorrhage[J].Neuropathol Exp Neurol,2017,76(5):358~375.
[4] 宿秀芳.鼠神经生长因子治疗新生儿颅内出血的疗效观察[J].中国实用神经疾病杂志,2017,20(11):88~90.
[5] Szpecht D, Nowak I, Kwiatkowska P, et al. Intraventricular hemorrhage in neonates born from 23 to 26 weeks of gestation: retrospective analysis of risk factors[J]. Adv Clin Exp Med, 2017,26(1):89~94.
[6] 中华医学会神经病学分会.中国脑出血诊治指南(2014)[J].中华神经科杂志,2015,48(6):435~444.
[7] 张晓燕,芦红茹,宋红霞,等.20项新生儿行为神经测定评分法对早产儿脑发育及脑损伤的评价[J].中国儿童保健杂志,2010,18(2):159~162.
[8] Rath D , Knorr C , Taylor U .Communication requested: boar semen transport through the uterus and possible consequences for insemination[J]. Theriogenology ,2016,85 (1):94~104.
[9] 班奕,万忠和.鼠神经生长因子对早产儿脑发育影响的研究[J].海南医学院学报,2016,22(9):860~863.
[10] 许马利,王杨.鼠神经生长因子治疗新生儿缺氧缺血性脑病的Meta分析[J].中国临床药理学杂志,2016,32(7):652~654.
[11] 刘向红,郎玉洁.鼠神经生长因子对新生儿缺氧缺血性脑病的安全性及疗效[J].实用临床医药杂志,2015,19(13):193~194.
[12] 赵乐,曹毅.尼莫地平在aSAH治疗中的研究进展[J].中国临床神经外科杂志,2017,22(2):115~117.
[13] 郑丽萍,许允成.血小板活化因子监测对新生儿缺氧缺血性脑病治疗效果评价的临床意义[J].河北医学,2015,21(1):131~134.
[14] 吕丽娜,王淑兰,闫学爽,等.超声联合MMP-2、MMP-9、CNP对新生儿颅内出血的诊断效果[J].检验医学与临床,2017,14(22):3402~3404. |
|
|
|
2019, Vol. 25 
